Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 840-848

  Kim, Michael H ^a   Klingman, David ^b   Lin, Jay ^c   Pathak, Prathamesh ^b   Battleman, David ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b IQVIA   (United States)

^c SANOFI   (France)

Author keywords

Atrial fibrillation; Dofetilide; Drug initiation; Sotalol

Indexed keywords

DOFETILIDE; SOTALOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; ELECTROCARDIOGRAPHY; EMERGENCY CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; RETROSPECTIVE STUDIES; SOTALOL; SULFONAMIDES;

EID: 65849427525     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L698     Document Type: Article

References (36)

1. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-356 DOI 10.1111/j.1524-4733.2006.00124.x (Pubitemid 44337788)
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375 (Pubitemid 32424106)
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114: 119-125 Epub 3 Jul 2006. DOI 10.1161/CIRCULATIONAHA.105.595140 (Pubitemid 44420743)
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457 (Pubitemid 24208570)
6. Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2008;51:865-884 DOI 10.1016/j.jacc.2008.01.006
7. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51:810-815 DOI 10.1016/j.jacc.2007.09.065
8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84. DOI 10.1016/S0002-9343(99) 80348-80349
9. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448 e1-448e19. DOI 10.1016/j.amjmed.2005.10.057
10. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999;137:1062-1069
11. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. DOI 10.1161/CIRCULATIONAHA.106.177292
12. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872. DOI 10.1056/NEJMoa041705
13. Tran A, Vichiendilokkul A, Racine E, Milad A. Practical approach to the use and monitoring of dofetilide therapy. Am J Health Syst Pharm 2001; 58:2050-2059 (Pubitemid 33043389)
14. Product information. Tikosyn (dofetilide). New York: Pfizer Inc., revised November 1999.
15. Product information. Betapace (sotalol hydrochloride). Montville, NJ: Bayer HealthCare Pharmaceuticals Inc., revised April 2007.
16. Makaryus AN, Hametz CD, Cohen TJ, Jadonath RL. Should the initiation of antiarrhythmic therapy for atrial fibrillation occur in the hospital or out of the hospital? A review of the literature. J Invasive Cardiol 2004; 16:31-34 (Pubitemid 38082476)
17. Simons GR, Eisenstein EL, Shaw LJ, Mark DB, Pritchett EL. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol 1997;80:1551-1557 (Pubitemid 28011829)
18. Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 2004;40:971-977 DOI 10.1016/j.jvs.2004.08.023 (Pubitemid 39535229)
19. Blanchette CM, Wang PF, Joshi AV, Kruse P, Asmussen M, Saunders W. Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitals. Adv Ther 2006;23:54-67.
20. Delaney CP, Chang E, Senagore AJ, Broder M. Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database. Ann Surg 2008;247:819-824 DOI 10.1097/SLA. 0b013e31816d950e
21. Vekeman F, McKenzie RS, Lefebvre P, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm 2007;64:1943-1949. DOI 10.2146/ajhp060585
22. US Department of Labor. Consumer Price Index. http://data.bls.gov/cgi- bin/surveymost?cu (accessed 2008 Nov 16).
23. 3M Health Information Systems. All Patient Refined Diagnosis Related Groups (APR-DRGs): methodology overview. Wallingford, CT: 3M Health Information Systems, 1998.
24. HSS, Inc. Definitions manual for All-Payer Severity-adjusted DRG (APS-DRGs) Assignment. Germantown, MD: HSS, Inc., 2003.
25. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-633 Epub 19 Apr 2007. DOI 10.1111/j.1540-8167.2007.00819.x (Pubitemid 46800517)
26. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10:403-411 Epub 7 Mar 2008. DOI 10.1093/europace/ eun048
27. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-1699 DOI 10.1185/030079905X65475
28. Kozak LJ, Lees KA, DeFrances CJ. National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2006;(160):1-206.
29. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147:121-126
30. McBride D, Mattenklotz AM, Willich SN, Brüggenjürgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2008;12:293-301. Epub 24 Jul 2008. DOI 10.1111/j.1524-4733.2008.00416.x
31. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-234 (Pubitemid 28123885)
32. Ishak JK, Proskorovsky I, Guo S et al. Persistence with amiodarone or sotalol and its impact on recurrence of atrial fibrillation. Presented at: International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, November 8-11, 2008.
33. Zimetbaum P, Ho KK, Olshansky B, et al. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol 2003;91:81-83
34. Bickford CL, Spencer AP. Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm 2006; 12:254-259 (Pubitemid 47400615)
35. Khaykin Y, Wang X, Natale A, et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009;20:7-12.
36. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000;36:2242-2246